News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Clinical Study Validates Sequenta’s LymphoSIGHT™ Platform as More Sensitive Alternative to Flow Cytometry for Cancer Detection


10/16/2012 10:21:47 AM

SAN FRANCISCO--(BUSINESS WIRE)--Sequenta, Inc. today announced the publication in the journal BLOOD of two landmark studies involving more than 150 patients that demonstrate the company’s LymphoSIGHT™ next generation sequencing method is more sensitive than existing tools for detecting minimal residual disease (MRD). These studies provide clinical validation for the use of the LymphoSIGHT™ platform in the treatment of B cell acute lymphoblastic leukemia (ALL); the most common childhood cancer.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES